Looking up the ticker with the regulator···
0s · usually 20–30 seconds for a cold read
Looking up the ticker with the regulator···
0s · usually 20–30 seconds for a cold read
Pfizer Inc.
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice.
Weak signals across every dimension
Get notified when we ship meaningful updates. No spam, no daily noise.
1 of 5 met · composite in line with peers
Business quality, valuation against the sector, and position in the 52-week range — whether they line up or not.
Mixed signals
Profitability
3/4
Debt & liquidity
0/3
Efficiency
2/2
Pfizer's cash generation stands out against a sector backdrop of thinning returns. Free cash flow yield runs 6.9%, nearly double the sector median, and the company converts earnings into cash reliably—the last eight quarters show a beat rate strong enough to suggest consistent execution. Yet that strength sits atop a weakening foundation. Revenue grew -1.6% year over year, trailing the sector median 5.9% by -128%, and debt has climbed relative to EBITDA; Debt/EBITDA stands at 5.3×, +72% above the median. The F-Score of 5/9 reflects this scatter—profitability holds, but balance-sheet strain and slowing growth pull the signal down. Valuation offers some cushion: the P/B of 1.8× sits -74% below the sector median, and EV/EBITDA at 18.9× is -21% below. Consensus and the realized three-year earnings record align, so the market is not pricing in a recovery that the past does not support.
| Ticker | Name | F-Score | ROE | Revenue YoY | Op. margin |
|---|---|---|---|---|---|
| ABBV | AbbVie | 8/9 | 15 367% |
Quarter-by-quarter classification · a retrospective read by the current logic · not a price forecast
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice. The method did not see these quarters in real time; this is the current logic applied to past reports.
The market prices in earnings growth; analyst sentiment is weakening; has mostly beaten consensus.
Price against next year's expected earnings. The forward P/E already carries analyst optimism — read it alongside the “Versus consensus” line.
A forward P/E below the current one means the market expects earnings to grow; above it, to fall. The historical growth is realized figures from SEC filings, not a forecast.
The three-month change in the share of positive analyst ratings. This is sentiment, not an earnings-estimate revision, and not a call to act.
When Pfizer reports on 2026-11-02, track revenue year-over-year growth against the current 5.86% figure — already 128% below the sector median. Also check whether the F-Score profitability block (currently 3/4) holds, particularly operating cash flow relative to assets.
Focus on the debt section: a Debt/EBITDA of 3.06×, 72% above the sector median, warrants reading management's stated repayment schedule and covenant disclosures. The MD&A should clarify how Pfizer plans to deploy its FCF yield of 3.65% — one of its clearer relative strengths.
Pick two or three companies from the Health Care table in section 06 and line up one metric — EV/EBITDA or Debt/EBITDA works well given Pfizer's mixed profile at 24.1× and 3.06× respectively. The table is alphabetical with no ranking, so the comparison is yours to frame.
Steps you can check yourself, based on the figures in this brief.
Piotroski F-Score: nine binary tests of financial strength from the annual report. A ✓ marks a test passed, a dot (·) a test failed.
Over 4 years: -13%-82%+105%-8%
Over 4 years: 1.127.074.505.27
Over 4 years: +24%-41%+7%-2%
The context on the right shows how each figure compares with the sector median. The trend below tracks the change over recent fiscal years.
Beat consensus in 8 of 8 recent quarters — the company clears estimates regularly (consensus is often set conservatively).
Last quarter's EPS against consensus, plus the estimated date of the next report.
| +9% |
| 25% |
| ABT | Abbott | 6/9 | 13% | +6% | 18% |
| AMGN | Amgen | 7/9 | 106% | +10% | 25% |
| BMY | Bristol-Myers Squibb | 8/9 | 41% | -0% | — |
| CVS | CVS Health | 6/9 | 2% | +8% | 1% |
| DHR | Danaher | 5/9 | 7% | +3% | 19% |
| GILD | Gilead Sciences | 8/9 | 40% | +2% | 34% |
| ISRG | Intuitive Surgical | 6/9 | 17% | +21% | 29% |
| JNJ | Johnson & Johnson | 4/9 | 35% | +6% | — |
| LLY | Eli Lilly | 7/9 | 101% | +45% | — |
| MRK | Merck | 4/9 | 37% | +1% | — |
| PFE | Pfizer Inc. | 5/9 | 9% | -2% | — |
| TMO | Thermo Fisher | 5/9 | 13% | +4% | 17% |
| UNH | UnitedHealth | 7/9 | 18% | +12% | 4% |
A sample of 14 companies in the sector including the target, alphabetical, unranked. Data from the latest SEC annual reports.
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice.
A simplified retrospective read: no analyst forecast (not available historically); the source is the annual report as of the date, so neighbouring quarters can rest on the same data. Quarters with the same classification in a row are merged into one row — each row is one change in the read, not a separate quarter. One ticker is an illustration of the classification logic, not statistics. How we calculate →
The last few quarters are recent context, not a fixed rate. Consensus for near quarters is set low, so companies clear it routinely; over long horizons the forecasts run the other way, too high.
A description of what the market and analysts expect. Not a price forecast and not investment advice. Analyst forecasts run systematically optimistic over long horizons — read them with that discount.